Suggested remit - To appraise the clinical and cost effectiveness of pembrolizumab in combination with carboplatin and paclitaxel or nab-paclitaxel within its marketing authorisation for untreated metastatic squamous non-small-cell lung cancer.
 
Status In progress
Process STA 2018
ID number 1306

Provisional Schedule

Expected publication 04 July 2019

Project Team

Project lead Kate Moore

Email enquiries

Evidence Review Group / Assessment Group School of Health and Related Research (ScHARR)

Consultees

Companies sponsors Merck Sharp & Dohme (pembrolizumab)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Roy Castle Lung Cancer Foundation
Professional groups Association of Cancer Physicians
  British Thoracic Oncology Group
  British Thoracic Society
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists

Commentators

Comparator companies Accord Healthcare (cisplatin, carboplatin, docetaxel, gemcitabine, paclitaxel, vinorelbine) (Confidentiality agreement not signed, not participating)
  Celgene (paclitaxel)
  Dr Reddy’s Laboratories (docetaxel) (Confidentiality agreement not signed, not participating)
  Fresenius Kabi (paclitaxel) (Confidentiality agreement not signed, not participating)
  Hospira UK (cisplatin, carboplatin, docetaxel, gemcitabine, paclitaxel) (Confidentiality agreement not signed, not participating)
  Lilly UK (gemcitabine) (Confidentiality agreement not signed, not participating)
  Medac GmbH (docetaxel, gemcitabine, paclitaxel, vinorelbine) (Confidentiality agreement not signed, not participating)
  Merck Sharp & Dohme (pembrolizumab) (Confidentiality agreement not signed, not participating)
  Pfizer (carboplatin, cisplatin, docetaxel, gemcitabine, paclitaxel)
  Pierre Fabre (vinorelbine) (Confidentiality agreement not signed, not participating)
  Sun Pharma (carboplatin, gemcitabine) (Confidentiality agreement not signed, not participating)
  Sandoz (cisplatin) (Confidentiality agreement not signed, not participating)
  Sanofi (docetaxel) (Confidentiality agreement not signed, not participating)
  Seacross pharmaceuticals (docetaxel) (Confidentiality agreement not signed, not participating)
  Teva (carboplatin, cisplatin, docetaxel, paclitaxel) (Confidentiality agreement not signed, not participating)
General commentators All Wales Therapeutic and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Healthcare Improvement Scotland
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
24 August 2018 Invitation to participate
18 July 2018 As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of pembrolizumab with carboplatin and paclitaxel for untreated squamous non-small-cell lung cancer. Please note that the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in late August 2018.
22 May 2018 - 20 June 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
16 April 2018 Committee meeting: 1
28 September 2017 In progress, In progress

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance